


PHARMACEUTICAL 2022



Organogenesis Holdings Inc. Rank 23 of 475







PHARMACEUTICAL 2022





Organogenesis Holdings Inc. Rank 23 of 475

The relative strengths and weaknesses of Organogenesis Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Organogenesis Holdings Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 617% points. The greatest weakness of Organogenesis Holdings Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 114% points.

The company's Economic Capital Ratio, given in the ranking table, is 202%, being 479% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	226,979
Cost of Goods Sold	114,199
Intangible Assets	54,445
Liabilities, Current	82,005
Liabilities, Non-Current	48,450
Other Assets	82,675
Other Compr. Net Income	0
Other Expenses	-31,116
Other Liabilities	70,769
Other Net Income	-9,132
Property and Equipment	79,160
Research and Development	30,742
Revenues	468,059
Selling, General and Administrative Expense	250,200

Output Variable	Value in 1000 USD
Assets	443,259
Liabilities	201,224
Expenses	364,025
Stockholders Equity	242,035
Net Income	94,902
Comprehensive Net Income	94,902
Economic Capital Ratio	202%